The effects of recombinant tissue-type plasminogen activator (rt-PA) on canine cadaver lung transplantation

Surgery Today

Volumn 29, Issue 8, 1999, Pages 747-754

  Akasaka, Shozo ^a   Nishi, Hideyuki ^a   Aoe, Motoi ^a   Date, Hiroshi ^a   Andou, Akio ^a   Shimizu, Nobuyoshi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Lung transplantation; Non heart beating donor; Recombinant tissue type plasminogen activator

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; PLASMINOGEN;

ADOLESCENT; ARTICLE; CADAVER DONOR; CONTROLLED STUDY; DOG; DRUG EFFECT; EXPERIMENTAL TRANSPLANTATION; GAS EXCHANGE; HEMOSTASIS; INTRAARTERIAL DRUG ADMINISTRATION; LUNG FUNCTION; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME;

EID: 0032781421     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02482320     Document Type: Article

References (22)

1. 1. Kayano K, Date H, Uno K, Shimizu N, Teramoto S (1993) Evaluation of viability of the canine cadaver lung for transplantation. Acta Med Okayama 47:329-337
2. 2. Umemori Y, Date H, Uno K, Aoe M, Ando A, Shimizu N (1995) Improved lung function by urokinase infusion in canine lung transplantation using non-heart-beating donor. Ann Thorac Surg 59:1513-1518
3. 3. Nishi H (1997) Successful canine cadaver lung transplantation after 18-hour preservation (in Japanese). Nippon Kokyuuki Geka Gakkai Zasshi (J Jpn Assoc Chest Surg) 11:25-33
4. 4. Date H, Matsumura A, Manchester JK, Obo H, Lima O, Cooper JM, Sundaresan S, Lowry OH, Cooper JD (1993) Evaluation of lung metabolism during successful twenty-four-hour canine lung preservation. J Thorac Cardiovasc Surg 105:480-491
5. 5. Clauss AV (1957) Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 17:237-246
6. 6. Friberger P, Knos M (1979) Plasminogen determination in human plasma. In: Scully MF, Kakkar VV (eds) Chromogenic peptide substrates: chemical and clinical usage. Churchill Livingstone, Edinburgh, pp 128-139
7. 7. Date H, Matsumura A, Manchester JK, Cooper JM, Lowry OH, Cooper JD (1993) Changes in alveolar oxygen and carbon dioxide concentration and oxygen consumption during lung preservation. J Thorac Cardiovasc Surg 105:492-501
8. 8. Novick RJ, Kenneth EG, Imtiaz SA, John L (1996) Lung Preservation: the importance of endothelial and alveolar type II cell integrity. Ann Thorac Surg 62:302-314
9. 9. Ulicny KS, Egan TM, Lambert CJ, Reddick RL, Wilcox BR (1993) Cadaver lung donors: effect of preharvest ventilation on graft function. Ann Thorac Surg 55:1185-1191
10. 10. Yamasaki F, Wada H, Aoki M, Inui K, Hitomi S (1989) An evaluation of the tolerance of autotransplanted canine lung against warm ischemia. Jpn J Surg 19:326-333
11. 11. Egan TM, Lambert CJ, Reddick RL, Ulicny KS, Keagy BA, Wilcox BR (1991) A strategy to increase the donor pool: use of cadaver lungs for transplantation. Ann Thorac Surg 52:1113-1121
12. 12. Egan TM, Ulicny KS, Lambert CJ, Wilcox BR (1993) Effect of a free radical scavenger on cadaver lung transplantation. Ann Thorac Surg 55:1453-1459
13. 13. Hoylaerts M, Rijken DC, Lijinen HR, Collen D (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem 257:2912-2919
14. 14. Petitpretz P, Simmoneau G, Cerrina J, Musset D, Dreyfus M, Vandenbroek MD, Duroux P (1984) Effects of a single bolus urokinase in patients with life-threatening pulmonary emboli: a descriptive trial. Circulation 70:861-866
15. 15. Editorial (1992) Thrombolysis for pulmonary embolism. Lancet 340:21-22
16. 16. Goldhaber SZ, Haire WD, Feldstein ML, Feldstein ML, Miller M, Toltzis R, Smith JL, Silva AT, Come PC, Lee RT, Parker JA, Mogtader A, Mcdonough TJ, Braunwald E (1993) Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 341:507-511
17. 17. Staub NC, Schulz EL, Albertine KH (1982) Leukocytes and pulmonary microvascular injury. Ann NY Acad Sci 384:332-343
18. 18. Agnelli G, Buchanan MR, Fernandez F, Boneu B, Van Ryn J, Hirsh J (1985) A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. Circulation 72:178-182
19. 19. Agnelli G, Buchanan MR, Fernandez F, Van Ryn J, Hirsh J (1985) Sustained thrombolysis with DNA-recombinant tissue-type plasminogen activator in rabbits. Blood 66:399-401
20. 20. Agnelli G, Buchanan MR, Fernandez F, Hirsh J (1985) The thrombolytic and hemorrhagic effects of tissue-type plasminogen activator: influence of dosage regimens in rabbits. Thromb Res 40:769-777
21. 21. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML, for the TIMI Investigators (1988) Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1-11
22. 22. Bovil EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hills LD, Lambrew CT, Leiboff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH, for the TIMI Investigators (1991) Hemorrhagic events during therapy with recombinant tissu-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI), phase II trial. Ann Intern Med 115:256-265